Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Rania Ali El-Farrash, Ain Shams University
ClinicalTrials.gov Identifier:
NCT01479114
First received: November 21, 2011
Last updated: November 24, 2011
Last verified: November 2011
  Purpose

The investigators aimed to evaluate the effect of G-CSF administration in septic neonates on neutrophil production and CD11b expression.


Condition Intervention Phase
Neonatal Sepsis
Drug: rh-GCSF
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: In Vivo Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on Neutrophilic Expression of CD11b in Septic Neonates

Resource links provided by NLM:


Further study details as provided by Ain Shams University:

Primary Outcome Measures:
  • all cause mortality [ Time Frame: one month ] [ Designated as safety issue: No ]

Enrollment: 90
Study Start Date: April 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: control group
Experimental: G-CSF group Drug: rh-GCSF
10 ug/kg/day intravenously for 3 days
Other Name: Granulocyte colony stimulating factor,neubogen,filgstrim
No Intervention: Non-GCSF group

Detailed Description:

Neonates are susceptible to septicemia secondary to quantitative and qualitative neutrophilic defects. Granulocyte-colony stimulating factor (G-CSF) stimulates myeloid progenitor cell proliferation and induces selective neutrophil functions.

  Eligibility

Ages Eligible for Study:   up to 4 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • newborn infants with postnatal age < 28 day,
  • minimum gestational age of 28 weeks and requiring intensive care with clinical signs consistent with the diagnosis of neonatal sepsis,
  • with or without neutropenia

Exclusion Criteria:

  • neonates with congenital malformation,
  • major chromosomal abnormalities,
  • prior use of cytokines or intravenous immunoglobulin, or decreased hemoglobin and/or hematocrit at or below the levels necessitate transfusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Rania Ali El-Farrash, Dr., Ain Shams University
ClinicalTrials.gov Identifier: NCT01479114     History of Changes
Other Study ID Numbers: MREC 09030
Study First Received: November 21, 2011
Last Updated: November 24, 2011
Health Authority: Egypt: Ministry of Health, Drug Policy and Planning Center

Additional relevant MeSH terms:
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Lenograstim
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 20, 2014